First Tracks Biotherapeutics, Inc.

First Tracks Biotherapeutics (TRAX) has recorded zero cyber incidents and zero red-flag 8-K filings over the past 90 days, suggesting operational stability in the near term. However, low signal in our window does not mean low risk; the full $49 Report pulls 12 months of filing history and adds dilution risk scoring, financing event context, and AI-detected risk signals that shape longer-term investor thesis. We also map officer departures, restatement patterns, and capital structure pressure points that short windows can miss. The full $49 Report adds comprehensive risk scoring, 12-month event timeline, and dilution analysis.